How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

438 results for

Nephrogenic Diabetes Insipidus

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Mutant vasopressin type II receptors associated with nephrogenic syndrome of inappropriate antidiuresis interact with {beta}-arrestin in an agonist-independent manner. (PubMed)

, and natriuresis. It was found that each infant had a different mutation of the vasopressin type II receptor (V2R) at codon 137 where arginine was converted to cysteine or leucine (R137C or R137L), resulting in constitutive signaling. Interestingly, a missense mutation at the same codon, converting arginine to histidine (R137H), leads to the opposite disease phenotype with a loss of the kidney's ability to concentrate urine resulting in nephrogenic diabetes insipidus. This mutation is associated with impaired (...) Mutant vasopressin type II receptors associated with nephrogenic syndrome of inappropriate antidiuresis interact with {beta}-arrestin in an agonist-independent manner. Nephrogenic syndrome of inappropriate antidiuresis is a recently identified genetic disease first described in two unrelated male infants with severe symptomatic hyponatremia. Despite undetectable arginine vasopressin levels, patients have inappropriately concentrated urine resulting in hyponatremia, hypoosmolality

Full Text available with Trip Pro

2009 Molecular Endocrinology

142. Thirsty Phursty: The Polydipsia Workup

with low solute intake. A 4-hour water restriction test began and was followed by DDAVP 2 mcg IV with results in Table 2. Table 2. Serum and Urine osmolarities during the water restriction test with DDAVP Final results of the water restriction test and administration of DDAVP revealed normal response with increased urine osmolarity to appropriate high levels. This ruled out a Central Diabetes Insipidus (CDI) and Nephrogenic Diabetes Insipidus (NDI) respectively. Osmotic Diuresis was excluded as her (...) in middle-aged women and is common in those with psychiatric disorders. Hypothalamic disorders have been reported to alter the thirst regulation center and systemic infiltrative disorders such as sarcoidosis can lead to this. A large number of medications can lead to dry mouth and thirst and must be ruled out as a cause prior to PP diagnosis. Differentiating PP from CDI and NDI is paramount on the urine studies. Central Diabetes Insipidus is lack of partial or complete ADH production. Nephrogenic

2017 Renal Fellow Network

143. Hepatitis B, Chronic

‐experienced children older than 2 and at least 10 kg, the entecavir doses are: 0.30 mg (10‐11 kg), 0.4 mg (>11‐14 kg), 0.5 mg (>14‐17 kg), 0.6 mg (>17‐20 kg), 0.7 mg (>20‐23 kg), 0.8 mg (>23‐26 kg), 0.9 mg (>26‐30 kg), and 1.0 mg (>30 kg). C Lactic acidosis Lactic acid levels if clinical concern Adefovir 10 mg daily ≥12 years 10 mg daily C Acute renal failure Fanconi syndrome Nephrogenic diabetes insipidus Lactic acidosis Creatinine clearance at baseline If at risk for renal impairment, creatinine (...) , and HDV) Heavy alcohol use Metabolic syndrome (obesity, diabetes) Concurrent viral infections (HCV, HIV, and HDV) Heavy alcohol use Metabolic syndrome (obesity, diabetes) Aflatoxin Smoking Diagnosis, Staging and Monitoring of Persons With CHB The initial evaluation of persons with CHB should include a thorough history and physical examination, with special emphasis on risk factors for coinfection, alcohol use, and family history of HBV infection and liver cancer. Laboratory tests should include

2015 American Association for the Study of Liver Diseases

144. Diagnosis, classification and staging of chronic kidney disease

“kidneys); and abnormalities in the composition of the blood and urine that define “tubular syndromes“(renal tubular acidosis, nephrogenic diabetes insipidus, Fanconi syndrome, etc). The K/DOQI guidelines address the clinical relevance of these abnormalities based on whether they “can lead to decreased kidney function.” This language is included in the definition of CKD (Table 3). I.A.6. Consider all kidney transplants recipients to have chronic kidney disease, irrespective of GFR level or presence (...) 3 months, irrespective of the underlying cause and on the basis of: (1C) an estimated or measured glomerular filtration rate 25 (M) >35 (F) >300 >40 (M) >60 (F) >500 *When reporting kidney function, stage (stages 1-5) is combined with kidney damage (albuminuria/proteinuria (Norm/Micro/Macro-albuminuria)) and clinical diagnosis to fully specify CKD stage (eg Stage 2 CKD with microalbuminuria secondary to diabetic nephropathy). Note: These staging criteria are the same for all races and gender. c

2013 KHA-CARI Guidelines

145. Case report: a thiazide diuretic to treat polyuria induced by tolvaptan. (PubMed)

Case report: a thiazide diuretic to treat polyuria induced by tolvaptan. Currently, the vasopressin V2 receptor antagonist tolvaptan is the only available treatment for autosomal dominant polycystic kidney disease (ADPKD), but there are tolerability issues due to aquaretic side-effects such as polyuria. A possible strategy to ameliorate these side-effects may be addition of a thiazide diuretic, this is an established treatment in nephrogenic diabetes insipidus, a condition where vasopressin V2

Full Text available with Trip Pro

2018 BMC Nephrology

146. Effects of sildenafil, metformin, and simvastatin on ADH‐independent urine concentration in healthy volunteers (PubMed)

Effects of sildenafil, metformin, and simvastatin on ADH‐independent urine concentration in healthy volunteers Nephrogenic diabetes insipidus (NDI) is a rare disorder characterized by resistance of the kidney to the action of antidiuretic hormone (ADH), resulting in a decrease in the capacity of the kidney to concentrate the urine. NDI can be inherited or acquired due to, for example, chronic lithium therapy. Current treatment options are limited to attempts to lower urine output by a low

Full Text available with Trip Pro

2018 Physiological reports

147. Copeptin levels and commonly used laboratory parameters in hospitalised patients with severe hypernatraemia - the “Co-MED study” (PubMed)

%]), followed by salt overload (SO) (n = 20 [22%]), central diabetes insipidus (CDI) (n = 5 [5%]) and nephrogenic diabetes insipidus (NDI) (n = 2 [2%]). Low urine osmolality was indicative for patients with CDI and NDI (P < 0.01). Patients with CDI had lower copeptin levels than patients with DH or SO (both P < 0.01) or those with NDI. Copeptin identified CDI with an AUC of 0.99 (95% CI 0.97-1.00), and a cut-off value ≤ 4.4pmol/L showed a sensitivity of 100% and a specificity of 99% to predict CDI

Full Text available with Trip Pro

2018 Critical Care

148. Structural Basis for Mutations of Human Aquaporins Associated to Genetic Diseases (PubMed)

Structural Basis for Mutations of Human Aquaporins Associated to Genetic Diseases Aquaporins (AQPs) are among the best structural-characterized membrane proteins, fulfilling the role of allowing water flux across cellular membranes. Thus far, 34 single amino acid polymorphisms have been reported in HUMSAVAR for human aquaporins as disease-related. They affect AQP2, AQP5 and AQP8, where they are associated with nephrogenic diabetes insipidus, keratoderma and colorectal cancer, respectively

Full Text available with Trip Pro

2018 International journal of molecular sciences

149. The Emerging Role of microRNAs in Aquaporin Regulation (PubMed)

The Emerging Role of microRNAs in Aquaporin Regulation Aquaporins (AQPs) are membrane channels widely distributed in human tissues. AQPs are essential for water and energy homeostasis being involved in a broad range of pathophysiological processes such as edema, brain injury, glaucoma, nephrogenic diabetes insipidus, salivary and lacrimal gland dysfunction, cancer, obesity and related metabolic complications. Compelling evidence indicates that AQPs are targets for therapeutic intervention

Full Text available with Trip Pro

2018 Frontiers in chemistry

150. Safety and Efficacy of Hydrochlorothiazide in the Treatment of Hypernatremia in Critically Ill Patients

to hydrochlorothiazide or other thiazides. Nephrogenic Diabetes Insipidus. Renal impairment KDIGO 3 Indication of renal replacement therapy. Acute neurological insult. Heart failure American Heart Association classification (AHA), class D. Liver cirrhosis Child-Pugh C. Pregnant women Exclusive palliative care Dying, with expected survival less than 48 hours Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research

2018 Clinical Trials

151. Lithium and nephrotoxicity: a literature review of approaches to clinical management and risk stratification. (PubMed)

Lithium and nephrotoxicity: a literature review of approaches to clinical management and risk stratification. Despite lithium being the most efficacious treatment for bipolar disorder, its use has been decreasing at least in part due to concerns about its potential to cause significant nephrotoxicity. Whilst the ability of lithium to cause nephrogenic diabetes insipidus is well established, its ability to cause chronic kidney disease is a much more vexing issue, with various studies suggesting (...) both positive and negative causality. Despite these differences, the weight of evidence suggests that lithium has the potential to cause end stage kidney disease, albeit over a prolonged period.A search strategy for this review was developed to identify appropriate studies, sourced from the electronic databases EMBASE, PubMed (NLM) and MEDLINE. Search terms included lithium with the AND operator to combine with nephrotoxicity or nephropathy or chronic kidney disease or nephrogenic diabetes

Full Text available with Trip Pro

2018 BMC Nephrology

152. Bile Acid G Protein-Coupled Membrane Receptor TGR5 Modulates Aquaporin 2-Mediated Water Homeostasis. (PubMed)

signaling on aquaporin-2 (AQP2) expression, and examined the in vivo effects of TGR5 in mice with lithium-induced nephrogenic diabetes insipidus (NDI) and Tgr5 knockout (Tgr5-/-) mice.Activation of TGR5 by lithocholic acid (LCA), an endogenous TGR5 ligand, or INT-777, a synthetic TGR5-specific agonist, induced AQP2 expression and intracellular trafficking in rat IMCD cells via a cAMP-protein kinase A signaling pathway. In mice with NDI, dietary supplementation with LCA markedly decreased urine output

2018 Journal of the American Society of Nephrology

153. Trial Investigating the Long Term Safety and Tolerability of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Subjects

at Visit 1a History of any neurological disease affecting bladder function or muscle strength at Visit 1a Habitual or psychogenic polydipsia based on medical history at Visit 1a or 24-hour urine output of >2.8 L based on the voiding diary at Visit 1b Central or nephrogenic diabetes insipidus at Visit 1a Syndrome of inappropriate antidiuretic hormone secretion at Visit 1a Suspicion or evidence of cardiac failure at Visit 1a Uncontrolled hypertension at Visit 1a and Visit 1b Hyponatraemia (serum sodium

2017 Clinical Trials

154. Lithium induces aerobic glycolysis and glutaminolysis in collecting duct principal cells. (PubMed)

Lithium induces aerobic glycolysis and glutaminolysis in collecting duct principal cells. Lithium, given to bipolar disorder patients, causes nephrogenic diabetes insipidus (Li-NDI), a urinary-concentrating defect. Li-NDI occurs due to downregulation of principal cell AQP2 expression, which coincides with principal cell proliferation. The metabolic effect of lithium on principal cells, however, is unknown and investigated here. In earlier studies, we showed that the carbonic anhydrase (CA

2017 American Journal of Physiology. Renal physiology

155. Liver X Receptor β (LXRβ) Increases AQP2 Protein Level via a Post-transcriptional Mechanism in Renal Collecting Ducts. (PubMed)

aquaporin 2 (AQP2) protein levels in renal collecting ducts. LXRβ-/- mice exhibited a reduced response to desmopressin (dDAVP) stimulation, suggesting that the diabetes insipidus phenotype is of both central and nephrogenic origin. AQP2 protein abundance in the renal inner medulla was significantly reduced in LXRβ-/- mice but with little change in AQP2 mRNA levels. In vitro studies showed that AQP2 protein levels were elevated upon LXR agonist treatment in both primary cultured mouse inner medullary

2017 American Journal of Physiology. Renal physiology

156. Lithium-induced NDI: Acetazolamide reduces polyuria, but does not improve urine concentrating ability. (PubMed)

Lithium-induced NDI: Acetazolamide reduces polyuria, but does not improve urine concentrating ability. Lithium is the mainstay treatment for patients with bipolar disorder, but it generally causes nephrogenic diabetes insipidus (NDI), a disorder in which the renal urine concentrating ability has become vasopressin insensitive. Li-NDI is caused by lithium uptake by collecting duct principal cells and downregulation of aquaporin-2 (AQP2) water channels, which are essential for water uptake from

2017 American Journal of Physiology. Renal physiology

157. A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults

, spina bifida) Habitual (fluid intake >3L per day) or psychogenic polydipsia Uncontrolled hypertension, as judged by the investigator Uncontrolled diabetes mellitus, as judged by the investigator Central or nephrogenic diabetes insipidus Known history of Syndrome of Inappropriate Antidiuretic Hormone (SIADH) secretion History of gastric retention Suspicion or evidence of congestive heart failure, (New York Heart Association (NYHA) class II, III, IV) Hyponatraemia: Serum sodium level <135 mmol/L

2017 Clinical Trials

158. A New Optical Sweat Test Method Based on a Citric Acid-derived Multi-halide Sensor

diagnosis of Cystic Fibrosis (CF) OR Healthy volunteers Exclusion Criteria: Participants under medications or with disorders known to cause a positive error in the sweat test will be excluded in the study. Common causes of positive error in sweat test are mineralocorticoid hormone therapy, adrenal insufficiency, glycogen storage diseases, hypothyroidism, hypoparathyroidism, nephrogenic diabetes insipidus, G6PD deficiency or ectodermal dysplasia OR Any other skin or soft tissue disorders that could

2017 Clinical Trials

159. Prostaglandin E2 in the Regulation of Water Transport in Renal Collecting Ducts (PubMed)

mechanisms. Each EP receptor plays a unique role in regulating water reabsorption in renal collecting ducts. This brief review highlights the role of PGE₂ in the regulation of water reabsorption and discusses the involvement of each EP receptor subtype in renal collecting duct. A better understanding of the role of PGE₂ in renal water transport process may improve disease management strategies for water balance disorders, including nephrogenic diabetes insipidus.

Full Text available with Trip Pro

2017 International journal of molecular sciences

160. Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake

Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: - Age 18 to 65 years Exclusion Criteria: Known or probable central or nephrogenic Diabetes insipidus, based on patient's history Polyuria secondary to diabetes mellitus, hypokalemia, hypercalcemia Primary Polydipsia, defined as more than 4 liters fluid intake per day BMI <18 or >30kg/m2 Pregnancy Previous treatment with GLP-1 agonists within the last 3 month History of pancreatitis Severe renal

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>